CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avid Bioservices Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avid Bioservices Inc
14191 MYFORD ROAD
Phone: (714) 508-6100p:714 508-6100 TUSTIN, CA  92780  United States Ticker: CDMOCDMO
On March 11, 2024, the Audit Committee of the Avid Bioservices Inc’s Board of Directors determined, based on management’s recommendation and after consultation with Ernst & Young LLP, the Company’s independent registered public accounting firm, that as a result of the classification of the 2026 Notes as long-term liabilities, the consolidated financial statements for the quarters ended October 31, 2022, January 31, 2023, July 31, 2023 and October 31, 2023, and for the fiscal year ended April 30, 2023 should no longer be relied upon.
Business Summary
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
10/31/20234/30/2023YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board JosephCarleone 77 11/1/2017 11/1/2017
President, Chief Executive Officer, Director Nicholas S.Green 59 7/30/2020 7/30/2020
Chief Financial Officer Daniel R.Hart 49 8/1/2018 8/1/2018
9 additional Officers and Directors records available in full report.

Business Names
Business Name
CDMO
Peregrine (Beijing) Pharmaceutical Technology Ltd.
Peregrine Pharmaceuticals, Inc.
PPHM
Vascular Targeting Technologies, Inc.

General Information
Number of Employees: 365 (As of 4/30/2023)
Outstanding Shares: 63,239,238 (As of 11/27/2023)
Shareholders: 605
Stock Exchange: NASD
Federal Tax Id: 953698422
Fax Number: (714) 838-5817
Email Address: info@peregrineinc.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024